Skip to main content
. 2021 Nov;10(11):4664–4679. doi: 10.21037/tcr-21-1646

Figure 5.

Figure 5

Differences and prognostic value of XPO1 methylation. (A) Differences in the negative log (methylation β-value) of XPO1 in the normal and tumor tissues of the 33 tumor types (**, P<0.01; ***, P<0.001. The P value of each tumor: BLCA: 0.001; BRCA: 0.08; CESC: 0.423; CHOL: 1; COAD: 0.623; ESCA: 0.601; GBM: 0.665; HNSC: 0.808; KIRC: 0.237; KIRP: 2.18e-05; LIHC: 3.47e-06; LUAD: 0.062; LUSC: 0.321; PAAD: 0.354; PCPG: 0.275; PRAD: 1.15e-06; READ: 0.836; SKCM: 0.115; THCA: 0.003; THYM: 0.344; UCEC: 0.079). Kaplan-Meier analysis of OS with XPO1 methylation in (B) BLCA, (C) UCEC, (D) CHOL and (E) KIRC. XPO1, Exportin 1; BLCA, bladder carcinoma; BRCA, infiltrating ductal carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KIRC, kidney clear cell renal cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma/paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; THCA, thyroid carcinoma; THYM, thymic carcinoma; UCEC, uterine corpus endometrial carcinoma.